Austria hosts one of the EU’s last integrated penicillin production sites in Kundl, Tyrol, which received $58.66 million (€50 million) in modernization funding.
Vienna is developing the Life Science Center, a new complex designed to expand laboratory and office space for companies and institutions.
Austria is expanding its advanced manufacturing footprint. Novartis has invested $1.89 billion (€1.6 billion) in Austrian sites between 2015 and 2024, including $188.7 million (€160 million) in R&D and infrastructure in 2024 alone. Facilities in Kundl and Schaftenau focus on biologics, plasmid DNA, mRNA and drug-device combinations, and have maintained zero-contamination records in microbial fermentation since 2021.
Pfizer Manufacturing Austria produces around 15 million vaccine doses annually against TBE and meningococcal C.
Octapharma is investing $236 million (€200 million) in Vienna to add 220 employees and new logistics capacity by 2028.
Fresenius Kabi is expanding in Graz with $33 million (€28 million) more planned through 2026.
